First patient treated in Geron stem cell trial
WASHINGTON Oct 11 (Reuters) - Geron Corp (GERN.O) said on Monday that doctors have begun treating the first patient in the United States to receive human embryonic stem cells, but said the details of the landmark clinical trial are being kept confidential.
Geron has the first U.S. Food and Drug Administration license to use the controversial cells to treat people, in this case patients with new spinal cord injuries. (Reporting by Maggie Fox, editing by Gerald E. McCormick) ((Maggie.Fox@ThomsonReuters.com; Washington bureau newsroom 202-898-8492))
- Islamic State threat 'beyond anything we've seen': Pentagon
- Oklahoma City policeman arrested for raping women while on patrol
- U.S. says Russia must pull convoy from Ukraine or face more sanctions |
- Gaza gunmen execute 'collaborators'; mortar kills Israeli boy |
- Exclusive: Apple iPhone 6 screen snag leaves supply chain scrambling |